Brain cancer breakthrough? new CAR-NK cell trial targets glioblastoma
NCT ID NCT07480941
First seen Mar 28, 2026 · Last updated Jun 22, 2026 · Updated 14 times
Summary
This early-stage trial tests a new approach for people with recurrent glioblastoma, a fast-growing brain tumor. Doctors take immune cells called NK cells, engineer them to recognize and attack tumor cells, and deliver them directly into the brain. The study will check safety and find the best dose in 36 adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CAR-NK cells (immune cells engineered to attack brain tumor cells)
What this could lead to
If it works, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with very few effective therapies.
What could go wrong
This is a very early Phase 1 trial with only 36 participants, so safety and effectiveness are not yet proven. The treatment involves brain surgery and chemotherapy, which carry serious risks.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.